TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The investigators aimed to compare the efficacy of nasal intermittent mandatory ventilation (IMV) and nasal continuous positive airway pressure (CPAP) in early rescue surfactant treatment in preterm infants.


Options:
A: Arm Label: Nasal Continuous Positive Airway Pressure (CPAP); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal CPAP (SLE) | Arm Label: Nasal Intermittent Mandatory Ventilation (IMV); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal IMV (SLE) | Intervention Type: DEVICE; Name: Nasal CPAP (SLE); Assigned to Arm(s): Nasal Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Nasal IMV (SLE); Assigned to Arm(s): Nasal Intermittent Mandatory Ventilation (IMV)
B: Arm Label: PS Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PS Group | Arm Label: NCPAP Group; Type: EXPERIMENTAL; Interventions: Device: NCPAP Group | Arm Label: ISX Group; Type: EXPERIMENTAL; Interventions: Drug: ISX Group | Intervention Type: DRUG; Name: PS Group; Assigned to Arm(s): PS Group | Intervention Type: DEVICE; Name: NCPAP Group; Assigned to Arm(s): NCPAP Group | Intervention Type: DRUG; Name: ISX Group; Assigned to Arm(s): ISX Group
C: Arm Label: Propofol; Type: EXPERIMENTAL; Interventions: Drug: Propofol-Lipuro | Arm Label: medialipide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Propofol-Lipuro; Assigned to Arm(s): Propofol | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): medialipide
D: Arm Label: Surfactant and Low Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: Surfactant and High Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 91 to 95% | Arm Label: CPAP and Low Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: CPAP and High Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 91 to 95% | Intervention Type: DRUG; Name: Surfactant; Assigned to Arm(s): Surfactant and High Oxygen, Surfactant and Low Oxygen | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): CPAP and High Oxygen, CPAP and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 85 to 89%; Assigned to Arm(s): CPAP and Low Oxygen, Surfactant and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 91 to 95%; Assigned to Arm(s): CPAP and High Oxygen, Surfactant and High Oxygen

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of a Need-based Nutritional Intervention Strategy to Improve the Nutritional Status of Elderly Nursing Home Residents
Brief Summary: To examine the effectiveness of a "need-based nutritional intervention" strategy in improving the nutritional and physical functional status of nursing home elderly.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as usual | Arm Label: Received nutrition supplement as needed; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Nutritional supplement, Other: Treatment as usual | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutritional supplement; Assigned to Arm(s): Received nutrition supplement as needed | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Control, Received nutrition supplement as needed
B: Intervention Type: BEHAVIORAL; Name: behavioral swallowing exercises/ strategies; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: "brain preservation' diet | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: "brain preservation' diet; Assigned to Arm(s): 1
D: Arm Label: Dietary Advice; Type: OTHER; Interventions: Behavioral: Dietary Advice | Arm Label: Oral Nutritional Supplements; Type: OTHER; Interventions: Dietary Supplement: Oral Nutritional Supplements (Fortisip) | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Dietary Advice | Intervention Type: DIETARY_SUPPLEMENT; Name: Oral Nutritional Supplements (Fortisip); Assigned to Arm(s): Oral Nutritional Supplements

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ADVANCE THERAPY ASPERGILLOSIS INVASIVE IN PATIENTS HIGH RISK ONCOHEMATOLOGICAL PCR USING FOR EARLY DETECTION OF ASPERGILLUS
Brief Summary: ADVANCE THERAPY ASPERGILLOSIS INVASIVE BY PCR DETECTION


Options:
A: Arm Label: High Risk Oncohematological Patients; Type: N/A; Interventions: Procedure: Aspergillus PCR technique, Procedure: Aspergillus AGA technique | Intervention Type: PROCEDURE; Name: Aspergillus PCR technique; Assigned to Arm(s): High Risk Oncohematological Patients | Intervention Type: PROCEDURE; Name: Aspergillus AGA technique; Assigned to Arm(s): High Risk Oncohematological Patients
B: Arm Label: Proven/Probable IA Patients; Type: N/A; Interventions: N/A | Arm Label: possible/No IA Patients; Type: N/A; Interventions: N/A
C: Arm Label: Standard diagnostic strategy of culture and histology; Type: ACTIVE_COMPARATOR; Interventions: Other: Culture and histology | Arm Label: Aspergillus galactomannan and PCR directed; Type: EXPERIMENTAL; Interventions: Other: Aspergillus galactomannan and PCR | Intervention Type: OTHER; Name: Culture and histology; Assigned to Arm(s): Standard diagnostic strategy of culture and histology | Intervention Type: OTHER; Name: Aspergillus galactomannan and PCR; Assigned to Arm(s): Aspergillus galactomannan and PCR directed
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ORAL VORICONAZOLE and IV Amphotericin B | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ORAL VORICONAZOLE and IV Amphotericin B | Intervention Type: DRUG; Name: ORAL VORICONAZOLE and IV Amphotericin B; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Brief Summary: Only an estimated 50 million US adults aged 50-75 are up-to-date on colorectal cancer (CRC) screening according to guidelines set by the federal government. CRC is 90% curable with timely detection and appropriate treatment of precancerous polyps; increased screening could reduce incidence by up to 50%. Groups least likely to undergo screening, those with minimal education, low income, low access to health care, recent immigrants or Hispanics, are the same people who frequently receive care at Federally Qualified Healthcare Center's (FQHCs). The use of fecal occult blood tests (FOBT) and fecal immunochemical tests (FIT) is exceedingly low in FQHCs (7-9% of patients in the past year) and far below national averages and target rates. Our results will provide valuable information on how to use electronic health record (EHR) resources to optimize guideline-based screening in FQHC clinics whose patient populations have disproportionately low CRC screening rates.

This project, in conjunction with the research team, will use an advisory panel to direct the research activities. The advisory panel will be made up of clinicians, leaders, researchers, and patients. The panel and team will guide the development of materials, the outreach to patients, and the research protocol to best reach FQHC patients who are due for colorectal cancer screening.

This project will be conducted in two phases, Phase I is conducting a pilot at two FQHC's, and Phase II is rolling out the intervention to between 20-30 clinics.


Options:
A: N/A
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group I; Type: EXPERIMENTAL; Interventions: Behavioral: self-regulation | Intervention Type: BEHAVIORAL; Name: self-regulation; Assigned to Arm(s): Intervention Group I
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Auto Plus; Type: ACTIVE_COMPARATOR; Interventions: Other: Auto Plus | Intervention Type: OTHER; Name: Auto Plus; Assigned to Arm(s): Auto Plus
D: Arm Label: Incentive schemes 1; Type: N/A; Interventions: N/A | Arm Label: Incentive schemes 2; Type: N/A; Interventions: N/A | Arm Label: Incentive schemes 3; Type: N/A; Interventions: N/A | Arm Label: Incentive schemes 4; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind Switch Study of Vilazodone in the Treatment of Major Depressive Disorder Following Partial Response to or Inability to Tolerate a Generic SSRI
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of vilazodone for the treatment of major depressive disorder versus citalopram. Doctors want to determine if vilazodone is effective for the treatment of major depressive disorder in those who have not responded to generic selective serotonin reuptake inhibitors (SSRI), which is a class of anti-depressant drugs such as Prozac, Lexapro, Paxil, or Zoloft. Both vilazodone and citalopram have been approved for the treatment of major depressive disorder. This research is being done because the researchers want to find out if vilazodone works in reducing the symptoms of depression significantly more than a generic SSRI.


Options:
A: Arm Label: Vilazodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vilazodone | Arm Label: Citalopram; Type: PLACEBO_COMPARATOR; Interventions: Drug: Citalopram | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Citalopram
B: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
C: Arm Label: Vilazodone 10mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 20mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 40mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 10mg, Vilazodone 20mg, Vilazodone 40mg
D: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacist Intervention Programme in Secondary Care to Improve Medication Adherence in Patients With Hypertension
Brief Summary: Patients with hypertension have an increased risk of stroke and myocardial infarction. However, poor adherence to treatment with antihypertensives and lipid-lowering agents occurs frequently within this patient group. The purpose of this study is to investigate whether a complex tailored intervention in a hospital setting will lead to increased medication adherence and fewer cardiovascular events when compared to a usual care group. Interventions focus on motivational interviewing, medication review and telephone follow up.


Options:
A: Arm Label: Systematic nurse-led GA; Type: EXPERIMENTAL; Interventions: Other: health care organization | Arm Label: GP-led GA on a case-by-case basis, as decided by the GP; Type: EXPERIMENTAL; Interventions: Other: health care organization | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: health care organization; Assigned to Arm(s): GP-led GA on a case-by-case basis, as decided by the GP, Systematic nurse-led GA
B: Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Complex tailored intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Complex tailored intervention | Intervention Type: BEHAVIORAL; Name: Complex tailored intervention; Assigned to Arm(s): Complex tailored intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
C: Intervention Type: BEHAVIORAL; Name: Comprehensive pharmacy care program; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Asprin / Clopidogrel, Atorvastatin / Simvastatin | Intervention Type: DRUG; Name: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asprin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacist Intervention Programme in Secondary Care to Improve Medication Adherence in Patients With Hypertension
Brief Summary: Patients with hypertension have an increased risk of stroke and myocardial infarction. However, poor adherence to treatment with antihypertensives and lipid-lowering agents occurs frequently within this patient group. The purpose of this study is to investigate whether a complex tailored intervention in a hospital setting will lead to increased medication adherence and fewer cardiovascular events when compared to a usual care group. Interventions focus on motivational interviewing, medication review and telephone follow up.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Physician/Pharmacist Collaborative Teams | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physician/Pharmacist Collaborative Teams; Assigned to Arm(s): Intervention
B: Arm Label: 1; Type: N/A; Interventions: Other: 1 | Arm Label: 2; Type: N/A; Interventions: Other: 2 | Intervention Type: OTHER; Name: 1; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: 2; Assigned to Arm(s): 2
C: Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Complex tailored intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Complex tailored intervention | Intervention Type: BEHAVIORAL; Name: Complex tailored intervention; Assigned to Arm(s): Complex tailored intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: Pharmacist-Physician Collaborative Medication Management; Type: EXPERIMENTAL; Interventions: Other: Pharmacist-Physician Collaborative Medication Therapy Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist-Physician Collaborative Medication Therapy Management; Assigned to Arm(s): Pharmacist-Physician Collaborative Medication Management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Brief Summary: Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: macitentan (ACT-064992) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: macitentan (ACT-064992) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: macitentan (ACT-064992); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: macitentan (ACT-064992); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 3
B: Arm Label: Macitentan; Type: EXPERIMENTAL; Interventions: Drug: Macitentan 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macitentan 10 mg; Assigned to Arm(s): Macitentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Bosentan administration; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aprocitentan 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 5 mg | Arm Label: Aprocitentan 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 10 mg | Arm Label: Aprocitentan 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 25 mg | Arm Label: Aprocitentan 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 50 mg | Arm Label: Lisinopril 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril 20 mg | Intervention Type: DRUG; Name: Aprocitentan 5 mg; Assigned to Arm(s): Aprocitentan 5 mg | Intervention Type: DRUG; Name: Aprocitentan 10 mg; Assigned to Arm(s): Aprocitentan 10 mg | Intervention Type: DRUG; Name: Aprocitentan 25 mg; Assigned to Arm(s): Aprocitentan 25 mg | Intervention Type: DRUG; Name: Aprocitentan 50 mg; Assigned to Arm(s): Aprocitentan 50 mg | Intervention Type: DRUG; Name: Lisinopril 20 mg; Assigned to Arm(s): Lisinopril 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hysteroscopy Before in Vitro Fertilization - Does it Improve the Outcome?
Brief Summary: By randomizing sub-fertile women to either control or office-hysteroscopy in the circle prior to IVF or ICSI (intracytoplasmatic sperm injection

) treatment, we aim to enlighten whether hysteroscopy with endometrial biopsy increases pregnancy rates in the intervention group.


Options:
A: Arm Label: endometrial scratch injury; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endometrial scratch injury | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endometrial scratch injury; Assigned to Arm(s): endometrial scratch injury
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Office-hysteroscopy with biopsy | Intervention Type: PROCEDURE; Name: Office-hysteroscopy with biopsy; Assigned to Arm(s): Intervention
C: Arm Label: Endometrial Biopsy; Type: EXPERIMENTAL; Interventions: Device: Endometrial Biopsy | Arm Label: Without Biopsy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Endometrial Biopsy; Assigned to Arm(s): Endometrial Biopsy
D: Arm Label: Endometrial Injury; Type: ACTIVE_COMPARATOR; Interventions: Other: Endometrial Injury | Arm Label: Luteal Phase Support; Type: ACTIVE_COMPARATOR; Interventions: Drug: progesterone (Crinone® %8 vaginal progesterone gel) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Endometrial Injury; Assigned to Arm(s): Endometrial Injury | Intervention Type: DRUG; Name: progesterone (Crinone® %8 vaginal progesterone gel); Assigned to Arm(s): Luteal Phase Support

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Trial of "My Meal Mate" (MMM), a Smartphone Application Designed to Facilitate Weight Loss.
Brief Summary: The aim of this study is to implement an exploratory pilot trial of "My Meal Mate" (MMM), a smartphone application developed to facilitate weight loss, assessing its feasibility and acceptability. Overweight and obese adults will be recruited from large employers within the local area. The trial will aim to recruit a sample size of 135 which is a pragmatic decision based on randomizing 45 people to each arm. Participants will be randomized to one of three groups. The researchers have developed a smartphone application for weight loss called "My Meal Mate" (MMM) which incorporates a large branded food and drink database. MMM was developed using focus group data collected from potential system users and by benchmarking with similar commercially available diet tracking applications. One group will receive a smartphone with the MMM app downloaded on it, one group will receive access to an online food diary and one group will be given a paper food diary. Participants will be asked to set a goal for weight loss and self-monitor their food intake and activity using their allocated study equipment. Participants will be weighed at the beginning of the trial, at 6 weeks and at 6 months. Feasibility and acceptability outcomes will be assessed.


Options:
A: Arm Label: Mood monitoring; Type: EXPERIMENTAL; Interventions: Device: Mobile Tracking Young People's Experiences (mobiletype) | Arm Label: Comparison monitoring program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Mobile Tracking Young People's Experiences (mobiletype); Assigned to Arm(s): Mood monitoring
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Check Your Drinking University version | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Check Your Drinking University version; Assigned to Arm(s): Intervention
C: Arm Label: Paper-based screening; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: E-screening; Type: EXPERIMENTAL; Interventions: Other: E-screening | Intervention Type: OTHER; Name: E-screening; Assigned to Arm(s): E-screening
D: Arm Label: Paper food diary; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Paper food diary | Arm Label: Online food diary; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Online food diary | Arm Label: "My Meal Mate" (smartphone application); Type: EXPERIMENTAL; Interventions: Behavioral: "My Meal Mate" (smartphone application) | Intervention Type: BEHAVIORAL; Name: "My Meal Mate" (smartphone application); Assigned to Arm(s): "My Meal Mate" (smartphone application) | Intervention Type: BEHAVIORAL; Name: Paper food diary; Assigned to Arm(s): Paper food diary | Intervention Type: BEHAVIORAL; Name: Online food diary; Assigned to Arm(s): Online food diary

Answer: D